Solution preparations

TW202633682APending Publication Date: 2026-08-16MIE UNIVERSITY +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
TW115102558
Authority / Receiving Office
TW · TW
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-03-30
Filing Date
2021-03-29
Publication Date
2026-08-16

Smart Images

  • Figure TWG2TA001073400_001
    Figure TWG2TA001073400_001
  • Figure TWG2TA001073400_002
    Figure TWG2TA001073400_002
  • Figure TWG2TA001073400_003
    Figure TWG2TA001073400_003
Patent Text Reader

Abstract

An antitumor agent comprising a solution formulation as an ingredient, the solution formulation comprising an antibody or a binding fragment thereof that specifically binds to human HLA / NY-ESO, and sugars and a buffer, wherein the antibody or the binding fragment thereof comprises: a heavy chain CDRH1 composed of an amino acid sequence represented by sequence identification number 54; a heavy chain CDRH2 composed of an amino acid sequence represented by sequence identification number 55; a heavy chain CDRH3 composed of an amino acid sequence represented by sequence identification number 56; a light chain CDRL1 composed of an amino acid sequence represented by sequence identification number 57, wherein the 7th amino acid is W; a light chain CDRL2 composed of an amino acid sequence represented by sequence identification number 58; and a light chain CDRL3 composed of an amino acid sequence represented by sequence identification number 59.
Need to check novelty before this filing date? Find Prior Art